Reward disturbances in antipsychotic-naïve patients with first-episode psychosis and their association to glutamate levels

Psychol Med. 2023 Mar;53(4):1629-1638. doi: 10.1017/S0033291721003305. Epub 2021 Aug 26.

Abstract

Background: Aberrant anticipation of motivational salient events and processing of outcome evaluation in striatal and prefrontal regions have been suggested to underlie psychosis. Altered glutamate levels have likewise been linked to schizophrenia. Glutamatergic abnormalities may affect the processing of motivational salience and outcome evaluation. It remains unresolved, whether glutamatergic dysfunction is associated with the coding of motivational salience and outcome evaluation in antipsychotic-naïve patients with first-episode psychosis.

Methods: Fifty-one antipsychotic-naïve patients with first-episode psychosis (22 ± 5.2 years, female/male: 31/20) and 52 healthy controls (HC) matched on age, sex, and parental education underwent functional magnetic resonance imaging and magnetic resonance spectroscopy (3T) in one session. Brain responses to motivational salience and negative outcome evaluation (NOE) were examined using a monetary incentive delay task. Glutamate levels were estimated in the left thalamus and anterior cingulate cortex using LCModel.

Results: Patients displayed a positive signal change to NOE in the caudate (p = 0.001) and dorsolateral prefrontal cortex (DLPFC; p = 0.003) compared to HC. No group difference was observed in motivational salience or in levels of glutamate. There was a different association between NOE signal in the caudate and DLPFC and thalamic glutamate levels in patients and HC due to a negative correlation in patients (caudate: p = 0.004, DLPFC: p = 0.005) that was not seen in HC.

Conclusions: Our findings confirm prior findings of abnormal outcome evaluation as a part of the pathophysiology of schizophrenia. The results also suggest a possible link between thalamic glutamate and NOE signaling in patients with first-episode psychosis.

Keywords: Functional magnetic resonance imaging; motivational salience; outcome evaluation; schizophrenia; spectroscopy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / therapeutic use
  • Female
  • Glutamic Acid
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Psychotic Disorders* / diagnostic imaging
  • Psychotic Disorders* / drug therapy
  • Reward
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents
  • Glutamic Acid